Stockwatch: Stale M&A And Valuations Limit A Sector Recovery
This article was originally published in Scrip
Last week the S&P 500 and NASDAQ Biotechnology (NBI) Indexes both finished the shortened trading week up about 1.3%. On the one hand, there's nothing like a long weekend to shift investors' perspective over to the sunny side of the street. On the other, the share prices of life science stocks remain volatile and investment bank analysts are still playing catch-up with downgrades to company share price targets.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.